Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Yongqiang Hua

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5101149318. Sources: OpenAlex.

Their work

Papers
18 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
49
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 3 papers · 2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: 1 paper · 2021: 4 papers · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper

Papers 18

  1. Nomogram for prognosis prediction in metastatic pancreatic cancer patients undergoing intra-arterial infusion chemotherapy: incorporating immune-inflammation s… Last author DOI 10.1186/s12885-025-13523-3↗
  2. Exploring the efficacy and safety of drug-eluting beads transarterial chemoembolization in pancreatic cancer liver metastasis. Co-author DOI 10.1093/bjr/tqae059↗
  3. Digital subtraction angiography-guided pancreatic arterial infusion of GEMOX chemotherapy in advanced pancreatic adenocarcinoma: a phase II, open-label, random… Co-author DOI 10.1186/s12885-024-12695-8↗
  4. PI3K/AKT/mTOR pathway and its related molecules participate in PROK1 silence-induced anti-tumor effects on pancreatic cancer. Co-author DOI 10.1515/biol-2022-0538↗
  5. Fam83D promotes tumorigenesis and gemcitabine resistance of pancreatic adenocarcinoma through the Wnt/β-catenin pathway. Co-author DOI 10.1016/j.lfs.2021.119205↗
  6. Combined ablation-chemotherapy versus chemotherapy alone for pancreatic cancer with liver metastasis: a propensity score matching study. Co-author DOI 10.1080/17474124.2021.1869937↗
  7. CMTM8 as an LPA1-associated partner mediates lysophosphatidic acid-induced pancreatic cancer metastasis. Co-author DOI 10.21037/atm-20-1013↗
  8. NUCB1 Suppresses Growth and Shows Additive Effects With Gemcitabine in Pancreatic Ductal Adenocarcinoma via the Unfolded Protein Response. Co-author DOI 10.3389/fcell.2021.641836↗
  9. Albumin-to-alkaline phosphatase ratio serves as a prognostic indicator in unresectable pancreatic ductal adenocarcinoma: a propensity score matching analysis Co-author DOI 10.21203/rs.2.24244/v1↗
  10. Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer. First author DOI 10.1186/s12967-019-1782-x↗
  11. Long non-coding RNA LINC00346 promotes pancreatic cancer growth and gemcitabine resistance by sponging miR-188-3p to derepress BRD4 expression. Co-author DOI 10.1186/s13046-019-1055-9↗
  12. Long non-coding SBF2-AS1 acting as a competing endogenous RNA to sponge microRNA-142-3p to participate in gemcitabine resistance in pancreatic cancer via upreg… Co-author DOI 10.18632/aging.102307↗
  13. LncRNA AB209630 inhibits gemcitabine resistance cell proliferation by regulating PI3K/AKT signaling in pancreatic ductal adenocarcinoma. Last author DOI 10.3233/cbm-181182↗
  14. Low serum miR-373 predicts poor prognosis in patients with pancreatic cancer. Co-author DOI 10.3233/cbm-170231↗
  15. Nanog Predicts Poor Prognosis in Human Pancreatic Cancer and Is Downregulated by QingyihuaJi Formula in Pancreatic Cancer Stem Cells. Co-author DOI 10.1155/2016/7028289↗
  16. Is chronic hepatitis B infection a protective factor for the progression of advanced pancreatic ductal adenocarcinoma? An analysis from a large multicenter coh… Co-author DOI 10.18632/oncotarget.13000↗
  17. ROR functions as a ceRNA to regulate Nanog expression by sponging miR-145 and predicts poor prognosis in pancreatic cancer. Co-author DOI 10.18632/oncotarget.6450↗
  18. High expression of erythropoietin-producing hepatoma cell line-B2 (EphB2) predicts the efficiency of the Qingyihuaji formula treatment in pancreatic cancer CFP… Co-author DOI 10.3892/ol.2014.2134↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhouyu Ning · 9 shared papers, 2016–2024 · strength 1.11
  2. Zhen Chen · 11 shared papers, 2014–2024 · strength 1.03
  3. Zhiqiang Meng · 3 shared papers, 2021–2024 · strength 0.59
  4. Weidong Shi · 5 shared papers, 2016–2021 · strength 0.57
  5. Zhiqiang Meng · 7 shared papers, 2016–2021 · strength 0.56
  6. Lianyu Chen · 5 shared papers, 2016–2021 · strength 0.49
  7. Yifan Yang · 1 shared paper, 2025 · strength 0.42
  8. Luming Liu · 4 shared papers, 2017–2021 · strength 0.41
  9. Yehua Shen · 4 shared papers, 2014–2024 · strength 0.41
  10. Yan Xia · 2 shared papers, 2021–2024 · strength 0.39
  11. Ke Zhang · 3 shared papers, 2019–2021 · strength 0.39
  12. Hao Chen · 3 shared papers, 2014–2024 · strength 0.36
  13. Luming Liu · 4 shared papers, 2016–2021 · strength 0.34
  14. Hao Chen · 4 shared papers, 2016–2019 · strength 0.30
  15. Chenyue Zhang · 3 shared papers, 2016–2021 · strength 0.27
  16. Lanyun Feng · 2 shared papers, 2016–2024 · strength 0.24
  17. Changjing Huang · 1 shared paper, 2024 · strength 0.20
  18. Peng Wang · 1 shared paper, 2024 · strength 0.20
  19. Chien‐shan Cheng · 1 shared paper, 2024 · strength 0.20
  20. Feng Wang · 1 shared paper, 2023 · strength 0.18
  21. Fei Peng · 1 shared paper, 2023 · strength 0.18
  22. Yongfeng Hui · 1 shared paper, 2023 · strength 0.18
  23. Shu Dong · 2 shared papers, 2016–2020 · strength 0.16
  24. Ye Li · 1 shared paper, 2021 · strength 0.15
  25. Ye Li · 1 shared paper, 2021 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.